| Round Values | |
|---|---|
| Capital Requirement | € 1.3 M |
| Pre-Money Valuation | € 2 M |
| Time Covered | 18 months |
| Estimated Valuation after completion of current stage. | € 58 M |
Parkinson’s Disease is a neurodegenerative condition that progressively takes away the ability to move.
Parkinson’s Disease affects 13M people worldwide, with an estimation of 32M by 2050.
13M patients
worldwide
- 32M by 2050
- Average onset age: 50
- As early as 25
85 new diagnosis
per hour
Every hour, 85 people in the world are told they have Parkinson’s
$120 Bn burden
- US: $26 Bn
- Spain: $6.4 Bn
- UK: $2.5 Bn
PROBLEM
Gold-standard treatment (Levodopa) helps to partially recover movement but presents critical unmet needs.
Levodopa Limitations
Only partial recovery of movement.
Causes Dyskinesia -permanent uncontrollable movements-which leads:
Does not stop disease progression
SOLUTION
Lipea™ a breakthrough add-on therapy that would significantly increase patient quality of life.
Patient Benefits
Enhancement of movement recovery by 100%.
Reduces dyskinesia by 48%; allowing for:
Slows disease progression by 79%.
CURRENT ROUND
A € 1.3M investment expected to yield 13x return in 1½ years.
Key Use of Proceed
- R&D 55%
- Payroll 28%
- OpEx 17%
- R&D 55%
- Payroll 28%
- OpEx 17%
INFORMATION
Download Company & Scientific Information.
2. Confidential
2.1- Business Plan
2.2- Financial Plan
2.3 - Valuation excercise & Investor Return
2.4 - Corporate Documents
2.5 - Intellectual Property
2.6 - Financing Round Documentation
SUBSCRIBE
CONTACT
For further inquiries contact us at:
